Results about: cancer
- A group of scientists headed by Maria Macias, ICREA researcher at IRB Barcelona, describes the mechanism through which TGIF1 inhibits the activity of Smad proteins.
- The study, which used molecular and structural biology techniques to analyse this interaction, has been published in Nucleic Acids.
A new computational model has allowed researchers to identify new therapeutic targets that can attack cancer cells by lowering their intracellular pH.
The study, which is the result of collaboration between IRB Barcelona, the Moffitt Cancer Center, and the University of Maryland, has been published in Nature Communications.
A team headed by Manuel Serrano at IRB Barcelona has designed a drug encapsulation system that selectively targets senescent cells.
The study paves the way for therapeutic approaches to eliminate senescent cells in many diseases, such as pulmonary fibrosis and cancer.
Researchers at the Centre for Genomic Regulation (CRG) in collaboration with IRB Barcelona, developed a new method to systematically identify genes contributing to heritable cancer risk.
The study, published in Nature Communications, is a success story for data sharing and openness in science.
A new study in collaboration with the Genomic Instability and Cancer Laboratory at IRB Barcelona and led by the University of Copenhagen, reveals that TLK2 displays lower levels of activity in intellectual disability and that it is possible to inhibit it in breast cancer, where it is overactive.
The study suggests that the enzyme may be a target for potential therapies.